Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

DOI HANDLE HANDLE PDF PubMed 被引用文献22件
  • Wing-yan Au
    Department of Medicine, Queen Mary Hospital, Hong Kong, China;
  • Dennis D. Weisenburger
    Departments of Internal Medicine and Pathology and Microbiology, University of Nebraska Medical Center, Omaha;
  • Tanin Intragumtornchai
    Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;
  • Shigeo Nakamura
    Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan;
  • Won-Seog Kim
    Division of Haemato-Oncology, Department of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Korea; and
  • Ivy Sng
    Department of Pathology, Singapore General Hospital, Singapore
  • Julie Vose
    Departments of Internal Medicine and Pathology and Microbiology, University of Nebraska Medical Center, Omaha;
  • James O. Armitage
    Departments of Internal Medicine and Pathology and Microbiology, University of Nebraska Medical Center, Omaha;
  • Raymond Liang
    Department of Medicine, Queen Mary Hospital, Hong Kong, China;

書誌事項

公開日
2009-04-23
DOI
  • 10.1182/blood-2008-10-185256
公開者
American Society of Hematology

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Among 1153 new adult cases of peripheral/T-cell lymphoma from 1990-2002 at 22 centers in 13 countries, 136 cases (11.8%) of extranodal natural killer (NK)/T-cell lymphoma were identified (nasal 68%, extranasal 26%, aggressive/unclassifiable 6%). The disease frequency was higher in Asian than in Western countries and in Continental Asia than in Japan. There were no differences in age, sex, ethnicity, or immunophenotypic profile between the nasal and extranasal cases, but the latter had more adverse clinical features. The median overall survival (OS) was better in nasal compared with the extranasal cases in early- (2.96 vs 0.36 years, P < .001) and late-stage disease (0.8 vs 0.28 years, P = .031). The addition of radiotherapy for early-stage nasal cases yielded survival benefit (P = .045). Among nasal cases, both the International Prognostic Index (P = .006) and Korean NK/T-cell Prognostic Index (P < .001) were prognostic. In addition, Ki67 proliferation greater than 50%, transformed tumor cells greater than 40%, elevated C-reactive protein level (CRP), anemia (< 11 g/dL) and thrombocytopenia (< 150 × 109/L) predicts poorer OS for nasal disease. No histologic or clinical feature was predictive in extranasal disease. We conclude that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma. However, the underlying features responsible for these differences remain to be defined.</jats:p>

収録刊行物

  • Blood

    Blood 113 (17), 3931-3937, 2009-04-23

    American Society of Hematology

被引用文献 (22)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ